TP53 and liver cancer: No significant difference was observed in OS or RFS between HCV‐SVR‐DAA and HCV‐SVR‐IFN in the present cohort, although cases with TP53 mutation had significantly shorter OS in comparison to cases without TP53 mutations in the TCGA liver cancer cohort (Figure S7).